US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

33.10

0.0000

Volume:160.00

Turnover:5.30K

Market Cap:162.83M

PE:- -

High:33.10

Open:33.10

Low:33.10

Close:33.10

52wk High:34.00

52wk Low:25.63

Shares:4.92M

Float Shares:4.53M

Volume Ratio:0.02

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Why Is ADC Therapeutics Plunging Today

Benzinga_recent_news

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Press Release: Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Firstgroup doubles down on open access expansion despite DfT concerns

Press Release: Immatics Announces Third Quarter 2025 Financial Results and Business Update

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Press Release: BeyondSpring Reports Third--Quarter 2025 Financial Results and Provides Corporate Update

Press Release: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":33.095,"timestamp":1766069812795,"preClose":33.095,"halted":0,"volume":160,"delay":0,"floatShares":4530000,"shares":4920000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"12-18 09:57:50 EST","open":33.095,"high":33.095,"low":33.095,"amount":5303.48208,"amplitude":0,"askPrice":33.42,"askSize":100,"bidPrice":33.06,"bidSize":900,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766091600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":33.095,"sharesOutstanding":4920000,"nav":33.16,"aum":163147200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.12,"preClose":33.095,"latestTime":"18:32 EST","volume":30,"amount":991.93,"timestamp":1766014373725},"volumeRatio":0.016085},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4530000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.016085,"shares":4920000,"dividePrice":0,"high":33.095,"amplitude":0,"preClose":33.095,"low":33.095,"week52Low":25.63,"pbRate":"--","week52High":34,"institutionHeld":0,"latestPrice":33.095,"committee":0.8,"eps":0,"divideRate":0,"volume":160,"delay":0,"ttmEps":0,"open":33.095,"prevYearClose":25.88,"prevWeekClose":33.4384,"prevMonthClose":33.5975,"prevQuarterClose":31.475,"fiveDayClose":33.5884,"twentyDayClose":32.9,"sixtyDayClose":31.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589857841","title":"ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589857841","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589857841?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:45","pubTimestamp":1764902700,"startTime":"0","endTime":"0","summary":"Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200427/0/en/ORIC-Pharmaceuticals-Presents-Potential-Best-in-Class-Profile-for-Enozertinib-with-Robust-Systemic-and-CNS-Activity-in-1L-and-Previously-Treated-NSCLC-Patients-with-EGFR-Atypical-M.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","CNS","BK4563","ORR","QD","BK4503","BK4166","ORIC"],"gpt_icon":0},{"id":"2588029698","title":"Why Is ADC Therapeutics Plunging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2588029698","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588029698?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:40","pubTimestamp":1764790800,"startTime":"0","endTime":"0","summary":"Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, with enrollment ongoing into 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PR","CR","ADCT","SD","BK4213","BK4007","BK4161","LENZ","ORR","BK4080","BK4231","BK4505","BK4139","BK4539","ADC"],"gpt_icon":0},{"id":"2588405322","title":"Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588405322","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588405322?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680400,"startTime":"0","endTime":"0","summary":"Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patientsAIP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197884/0/en/Immutep-to-Present-New-Data-from-AIPAC-003-Phase-II-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU2265009873.SGD","BK4144","BK4139","BK4590","BK4585","ALC","BK4198","IMMP","BK4086","BK4581","LU0053666078.USD","LU2487616109.SGD","BK4107","BK4561","LU1169589451.USD","LU1804176565.USD","ET","LU1169590202.USD","BK4588","BK4534","ORR","LU0210528500.USD","MBC","L","PD"],"gpt_icon":0},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK4218","PK","IE00B66KJ199.SGD","CRS","BK4181","ORR","BK4006","IE0031619046.USD","IND","IE00B19Z4B17.USD","ORR.AU","BK4187","IE00B7SZL793.SGD","CRS.AU","ADC.AU","LU2065731478.USD","LU0963586101.USD","BK4080","BK4231","BK7095","ADC"],"gpt_icon":0},{"id":"2586782177","title":"Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782177","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782177?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:52","pubTimestamp":1764334320,"startTime":"0","endTime":"0","summary":"BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd.  announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel  , has received new drug marketing approvalfrom the China National Medical Products Administration . This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma  after two or more lines of systemic therapy. This is the second approved indicationin China for Ina-cel, following its initial approval in November 2023 for the treatment of adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia . This milestone marks the first proprietary CD19 CAR-T product in China with full intellectual property rights to become the only CAR-T cell therapy product in the country that covers both leukemia and lymphoma, the two major hematological oncology indications.Professor Dehui Zou, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences :","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/inaticabtagene-autoleucel-yorwidatm-new-drug-application-for-lymphoma-approved-chinas-innovative-car-t-enters-a-new-era-of-dual-indications-302628059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","ORR","LU0963586101.USD","BK4022","IE00B19Z4B17.USD","BK4230","BK4187","CR","BK4161","IE0031619046.USD","IE00B7SZL793.SGD","CRS.AU","BK7095","ORR.AU","BK4006","CAR","LU2065731478.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2586341936","title":"Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586341936?lang=en_us&edition=fundamental","pubTime":"2025-11-25 08:00","pubTimestamp":1764028800,"startTime":"0","endTime":"0","summary":"Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3193993/0/en/Ascentage-Pharma-Announces-Publication-of-Olverembatinib-Phase-Ib-Safety-Efficacy-and-Novel-Mechanism-Data-in-Gastrointestinal-Stromal-Tumors-in-Nature-s-Signal-Transduction-and-Ta.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","LU1223082519.USD","BK4017","LU1223082196.USD","LU1223083913.SGD","ORR","AAPG","BK4139"],"gpt_icon":0},{"id":"2585625504","title":"Press Release: Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585625504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585625504?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989200,"startTime":"0","endTime":"0","summary":"Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial. 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months. The median time to next treatment  following initiation of OJEMDA exceeded 3.5 years. BRISBANE, Calif., Nov. 24, 2025  -- Day One Biopharmaceuticals, Inc.  , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced three-year results from the OJEMDA pivotal Phase 2 FIREFLY-1 trial in an oral presentation at the 30 Annual Meeting & Education Day of the Society for Neuro-Oncology .\"We are excited by these updated three-year data showing that patients taking tovorafenib were able to spend meaningful time off therapy, with the option to retreat as needed,\" said Elly Barry, MD, Chief Medical Officer of Day One. \"These findings highlight the potential for a treatm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","BK4585","BK4555","ORR","TM","BK4604","03160","BK4099","BK4139","DAWN"],"gpt_icon":0},{"id":"2585014987","title":"MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2585014987","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585014987?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:01","pubTimestamp":1763733660,"startTime":"0","endTime":"0","summary":"Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov.  21, 2025  (GLOBE NEWSW","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/21/3192819/0/en/MAIA-Biotechnology-Highlights-Ongoing-Momentum-of-Ateganosine-Clinical-Program-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","SG9999011746.SGD","IE00BYTNYN87.SGD","L","BK4097","IE00BYQNZ168.SGD","IE00B12V2V27.USD","BK4588","LU0053666078.USD","BK4139","BK1541","IE0003851619.USD","BK1103","CPI","BK4081","01308","BK4107","IE0003795394.USD","MAIA","OS","ORR","LU2487616109.SGD","LU0210528500.USD","BK4585"],"gpt_icon":0},{"id":"2584913273","title":"MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2584913273","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584913273?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:47","pubTimestamp":1763646420,"startTime":"0","endTime":"0","summary":"Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov.  20, 2025  (GLOBE NEWSWIRE) -- MAIA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191938/0/en/MAIA-Biotechnology-CEO-Presents-Telomere-Targeting-Efficacy-at-Romania-s-2025-Smart-Diaspora-Conference-on-Oncology-Research-and-Innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4585","BK4107","BK4588","LU0053666078.USD","BK4139","ORR","L","LU2487616109.SGD","LU0210528500.USD","CPI"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"us","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","IE00B19Z4B17.USD","PRGS","BK4161","LU2065732104.USD","BK7508","IE0031619046.USD","IE00B7SZL793.SGD","CRS","CR","BK7096","ACR.AU","BK7095","ORR","IE00B66KJ199.SGD","LU0963586101.USD","BK4110","BK4006","BK4187","ACR","IND.AU","CRS.AU","LU2065731478.USD","ORR.AU"],"gpt_icon":0},{"id":"2584957554","title":"Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957554","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584957554?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:58","pubTimestamp":1763488680,"startTime":"0","endTime":"0","summary":"Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/18/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/18/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/48931917/major-victory-for-genmab-as-epkinly-receives-fda-approval-for-type-of-pretreated-blood-cancer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/48931917/major-victory-for-genmab-as-epkinly-receives-fda-approval-for-type-of-pretreated-blood-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4195","BK4211","EC","BK4201","CR","ORR","PFS","GMAB","BK4139","BK4161"],"gpt_icon":0},{"id":"2584543559","title":"Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584543559","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584543559?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:30","pubTimestamp":1763483400,"startTime":"0","endTime":"0","summary":"Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3190331/0/en/Genmab-Announces-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-Approved-by-the-U-S-Food-and-Drug-Administration-for-the-Treatment-of-Relapsed-or-Refractor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4161","BK4006","LU0963586101.USD","LU2065731478.USD","ORR","BK4187","PFS","IE00B7SZL793.SGD","BK4195","CRS","CR","IE0031619046.USD"],"gpt_icon":0},{"id":"2584939824","title":"Firstgroup doubles down on open access expansion despite DfT concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939824","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939824?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:45","pubTimestamp":1763462700,"startTime":"0","endTime":"0","summary":"FirstGroup operates Lumo services Firstgroup has doubled down on its open access expansion plans as the transport business defied government concerns over the scheme.The FTSE 250 firm said it was “focused on growing” its operations in open access, an arrangement under which private rail operators will continue to run services after the nationalisation of all major routes as part of the government’s plans for public rail ownership.“Open access operators bring significant private investment to both the rail sector and UK manufacturing,” Firstgroup said.“Despite accounting for less than 1 per cent of the railway, open access has accounted for over a quarter of all new rolling stock investment during the last five years, creating jobs and supporting local supply chains.“We remain particularly concerned about the detrimental performance impacts that would be felt across the network if these applications are approved,” DfT said in a letter to the ORR in June.“Capacity is already severely con","market":"us","thumbnail":"https://www.cityam.com/wp-content/uploads/2025/11/Lumo-e1763461930405.png?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2025/11/Lumo-e1763461930405.png?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/firstgroup-doubles-down-on-open-access-expansion-despite-dft-concerns/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/firstgroup-doubles-down-on-open-access-expansion-despite-dft-concerns/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"gpt_icon":0},{"id":"2584640789","title":"Press Release: Immatics Announces Third Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584640789","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584640789?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:00","pubTimestamp":1763380800,"startTime":"0","endTime":"0","summary":"randomized, controlled Phase 3 trial, SUPRAME, in previously treated. advanced melanoma ongoing; interim and final analyses will occur in 2026. -- Anzu-cel  PRAME Cell Therapy: One-time infusion continues to show. strong clinical benefit and favorable tolerability in 16 patients with. metastatic uveal melanoma in latest update on Phase 1b data presented at. the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months,mPFS of 8.5 months and mOS not reached at 14.3 months mFU. -- IMA203CD8 PRAME Cell Therapy : Phase 1a clinical trial ongoing with. next data update, including dose escalation data in ovarian cancer,melanoma and synovial sarcoma, planned to be presented at ESMO. -- TCR Bispecifics: IMA402 and IMA401 TCR Bispecifics achieved clinical. and durable responses in heavily pre-treated, last-line patients with a. -- TCR Bispecifics data support development opportunities for IMA402 PRAME. Bispecific in cutaneous melanoma, gynecologic cancers and in combination. with IMA401","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","OS","PFS","ODD","IMTX","BK4195","BK4097","BK4211","BK4139","ORR"],"gpt_icon":0},{"id":"2584864263","title":"Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584864263","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584864263?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/17/3188936/0/en/Zymeworks-Announces-Positive-HERIZON-GEA-01-Phase-3-Results-Supporting-Ziihera-zanidatamab-hrii-as-HER2-Targeted-Agent-of-Choice-and-New-Standard-of-Care-in-First-Line-HER2-Positiv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","OS","BTC","BK4124","BK4097","BK4195","ORR","PFS","BK4211","BK4142","CHH"],"gpt_icon":0},{"id":"2583679215","title":"Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583679215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583679215?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden. Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors. Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index. Anticipate cash runway into the first quarter of 2027. WALTHAM, Mass., Nov. 13, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","BK4113","BK4231","BK4139","LU0053666078.USD","BK4080","BK4107","LENZ","BK4232","R","MSS","XLO","L","BK4588","BK4022","BK4007","TMB","BK4539","ORR","SITC","LU2487616109.SGD","BK4585"],"gpt_icon":0},{"id":"2583588639","title":"Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588639","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588639?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"-- Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR. T-cell product candidate that has demonstrated a 67% overall response. rate, an 83% disease control rate and a manageable safety profile at the. highest dose level studied to date in patients with refractory metastatic. colorectal cancer in an ongoing U.S. Phase 1 clinical trial. -- Received RMAT designation from the U.S. FDA for ronde-cel for the. treatment of patients with relapsed or refractory LBCL receiving. data from the Phase 1/2 clinical trial of ronde--cel for the treatment of. -- Announced the initiation of PiNACLE - H2H, a Phase 3 head-to-head CAR. SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025  -- Lyell Immunopharma, Inc. , a late-stage clinical company advancing next-generation chimeric antigen receptor  T-cell therapies for patients with cancer, today reported financial results and business highlights for the third quarter ended September 30, 2025.Lyell recently acquired exclusive global rights  to LYL27","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4139","GCC","BK4022","ORR","BK4539","BK4505","CAR","LYEL"],"gpt_icon":0},{"id":"2583048585","title":"Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583048585","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583048585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186774/0/en/Cue-Biopharma-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"2582373704","title":"Press Release: BeyondSpring Reports Third--Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373704","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373704?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"-- Two SITC 2025 presentations: First-in-class dendritic cell . maturation agent Plinabulin drives immune re-sensitization in metastatic. NSCLC patients who had progressed after PD-1/L1 inhibitors with disease. control rate of 85% in combination with docetaxel and Keytruda. Mechanism. studies with MD Anderson collaborators showed DC maturation and M1. macrophage polarization via a Plinabulin specific GEF-H1 dependent. mechanism in responding patients with Plinabulin, PD-1 inhibitor and. -- SEED, co-founded by BeyondSpring with 38% equity share, successfully. -- SEED Named Finalist for 2025 Prix Galien USA \"Best Start-Up\" Award. Dr. Huang added, \"At SEED, which we co-founded with Lilly five years ago, we are excited that our RBM39 molecular-glue degrader has received IND clearance from both the US FDA and China NMPA. It is such an honor to be the only target protein degradation company nominated by the Prix Galien Foundation, recognizing our commitment to developing transformative medic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4017","ORR","BK4588","BK4099","BK4604","BK4555","BYSI","BK4097","BK4211","DC","OS","BK4139","TM","03160","BK4585","BK4195"],"gpt_icon":0},{"id":"2582876379","title":"Press Release: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582876379","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582876379?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777800,"startTime":"0","endTime":"0","summary":"Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026. Updated data from Phase 2 IIT of ZYNLONTA  plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma. Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028. \"The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA  as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"We look forward to multiple upcoming clinical catalysts expected across LOTIS-7, LOTIS-5, and the ongoing Phase 2 IITs, starting with LOTIS-7 before the end of this year and continuing with data readouts throughout 2026.\". --","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4211","BK4007","PIPE","R","BK4231","CR","BK4505","PFS","BK4022","LENZ","BK4195","BK4161","BK4232","ORR","BK4080","BK4139","ADCT","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":141,"code":"91000000","status":"200"}]}}